Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
The Central Social Insurance Medical Council (Chuikyo) on August 7 approved 12 medicines for reimbursement listing later this month, with the largest peak sales projected for Novartis Pharma’s Fabhalta (iptacopan), a treatment for paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is expected…
To read the full story
Related Article
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
REGULATORY
- US Narrows Scope of Medicare MFN Model, Exempts Orphan-Only Drugs
October 2, 2026
- Japan to Draw Up Growth Strategy Action Plan by Year-End
October 2, 2026
- Chuikyo Backs Broader CEA Price Cuts This Year, Snubs Pharma Plea
October 1, 2026
- Repatha Optimal Use Guidelines to Be Simplified
October 1, 2026
- Label Revisions Ordered for Checkpoint Inhibitors over Gastritis, Esophagitis
September 30, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…